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Abstract
Background: Stem cells are increasingly seen as a solution for many health challenges for an ageing population.
However, their potential benefits in the clinic are currently curtailed by technical challenges such as high cell dose
requirements and point of care delivery, which pose sourcing and logistics challenges. Cell manufacturing solutions
are currently in development to address the supply issue, and ancillary technologies such as nanoparticle-based labelling
are being developed to improve stem cell delivery and enable post-treatment follow-up.
Methods: The application of magnetic particle (MP) labelling to potentially scalable cell manufacturing processes was
investigated in a range of therapeutically relevant cells, including mesenchymal stromal cells (MSC), cardiomyocytes
(CMC) and neural progenitor cells (ReN). The efficiency and the biological effect of particle labelling were analysed
using fluorescent imaging and cellular assays.
Results: Flow cytometry and fluorescent microscopy confirmed efficient labelling of monolayer cultures. Viability was
shown to be retained post labelling for all three cell types. MSC and CMC demonstrated higher tolerance to MP doses
up to 100× the standard concentration. This approach was also successful for MP labelling of suspension cultures,
demonstrating efficient MP uptake within 3 h, while cell viability was unaffected by this suspension labelling process.
Furthermore, a procedure to enable the storing of MP-labelled cell populations to facilitate cold chain transport to the
site of clinical use was investigated. When MP-labelled cells were stored in hypothermic conditions using HypoThermosol
solution for 24 h, cell viability and differentiation potential were retained post storage for ReN, MSC and beating CMC.
Conclusions: Our results show that a generic MP labelling strategy was successfully developed for a range of clinically
relevant cell populations, in both monolayer and suspension cultures. MP-labelled cell populations were able to undergo
transient low-temperature storage whilst maintaining functional capacity in vitro. These results suggest that this MP
labelling approach can be integrated into cell manufacturing and cold chain transport processes required for
future cell therapy approaches.
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Background
Emerging cell-based therapies are demonstrating prom-
ising solutions to a wide range of debilitating health con-
cerns facing global healthcare systems [1]. A number of
stem cell sources are currently being researched for a
range of potential applications yet challenges still exist,
particularly with reproducible manufacturing, distribu-
tion [2, 3] and minimising costs of goods [4]. In addition
to this, the mechanism of action underpinning many of
these therapies remains largely unknown and subsequent
cell dose requirements are high [5]. Better cell targeting
strategies may help overcome some of these challenges,
and magnetic particle (MP) labelling represents an at-
tractive means to facilitate this targeting [6]. Magnetic
targeting allows non-invasive imaging of administered
cells post implantation [7], which can help measure effi-
cacy and thus provide follow-up characterisation and
safety data in the early stages of development [8]. To-
gether, this spatial control over grafted cells and in-
creased understanding with follow-up imaging have the
potential to significantly improve the efficacy, specificity
and impact of cell therapies for patient benefit [9].
MPs possess a wide variety of interesting and sometimes
contrasting properties which make them useful for a
multitude of biological and biomedical applications. With
strong permanent magnets and superconducting electro-
magnets, a range of field strengths, gradients and dura-
tions are available for potential applications in multiple
medical disciplines. The use of small magnetic particles
for in-vitro diagnostics has been commonplace for almost
40 years [10–12]. The biomedical applications of magnetic
particles have evolved over these years into a multidiscip-
linary field, which harnesses magnetic materials for a var-
iety of applications. These multi-functional tools are often
described as theranostics and describe the delivery of an
active therapeutic payload to a cell whilst providing diag-
nostic information on its location [13].
The avenues that magnetic targeted therapeutics can
take are diverse, including active material coatings [14],
drug payloads [15] or targeted hyperthermia [16] to ab-
late carcinoma lesions at the cellular level. A multitude
of research groups are working towards creating label-
ling solutions for stem cells, cell therapies and regenera-
tive medicine products. The potential benefits of these
products could include both magnetic tracking [17] and
targeting [18] strategies, as well as sensory [19] and acti-
vation [20] particles.
MP cell tracking approaches are afforded through the
use of magnetic resonance imaging (MRI). MP-based
imaging stems from the first use of MRI contrast agents,
which emerged around 1981–1982 [21] and allow identi-
fication of specific labelled areas within biological organ-
isms. Recent advances in the MRI technique have
enabled real-time qualitative analysis of in-vivo tissues
providing real-time observations of disease progression
or therapeutic efficacy [19, 22]. MRI is also of benefit to
emerging targeting approaches using electromagnetic
fields to guide magnetic particles. This technique utilises
the magnetic scanner to guide magnetic objects and has
been demonstrated to successfully deliver cell suspen-
sions to the myocardium in animal models [23]. Per-
manent magnet-based approaches for magnetic cell
temporal control are more common and have been dem-
onstrated extensively in the wider literature. Magnetic
induced migration of labelled cells towards specific areas
in vivo has been shown for multiple tissue types, includ-
ing the vasculature [24–30], retina [31, 32], CNS [33]
and liver [34]. Finally, magnetically labelled cells have
demonstrated utility in construction and handling of cell
sheets for retinal applications [32] as well as engraftment
into scaffold-like structures such as stents [35, 36]. This
suggests some tissue engineering approaches may also
benefit from labelled cell sources.
Despite the capability promised by developers of MPs
to enhance the end regenerative medicine products [37],
few of these products have been validated for clinical use
[38]. Similarly, relatively little interest has been paid to
how these MP theranostics could be incorporated into
potentially scalable cell manufacturing platforms. Rather,
existing published research focuses on labelling strat-
egies in planar culture systems which would be unsuit-
able for wide-scale adoption [38]. Similarly, distribution
of cell-based therapies has been under-studied and only
recently is significant investment taking place in this
space [2].
In order to produce the quantities of biological material
for mainstream adoption of regenerative medicine and cell
therapies, scale up production methodologies are needed.
This should deliver any economies of scale and thus drive
production costs down. We have previously described a
safe and efficacious MP labelling strategy for human mes-
enchymal stromal cells (MSC) and demonstrated its utility
as a multifunctional cell tracking and manipulation tool
[38]. This paper describes labelling strategies using two
MP size ranges (500 nm and 1000 nm) to label three
therapeutically relevant stem cell populations: human
bone marrow-derived MSC, iPS-derived human cardio-
myocytes (CMC) and ReNeuron neural stem cells (ReN).
We further describe how this can be integrated into the
pooling or holding stage of a simulated cell manufacturing
process and how the resultant cell product could be
shipped at low temperature (4 °C) to a clinical environ-
ment in a ready-to-use state.
Methods
All reagents were purchased from ThermoFisher Scien-
tific (UK) unless otherwise stated.
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Human mesenchymal stromal cell culture
A human bone marrow-derived mesenchymal stromal
cell line [38] (also known as mesenchymal stem cells)
was cultured and expanded under standard cell culturing
conditions (37 °C, 5% CO2) in standard culture medium
consisting of Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% (v/v) FBS, 1% (v/v)
non-essential amino acids, 1 mM L-glutamine, 1 mM
pyruvate and 1% penicillin/streptomycin. Cells were pas-
saged using trypsin/EDTA. Primary mesenchymal stro-
mal cells (pMSC) were isolated from human bone
marrow aspirate (Lonza, UK) [39].
Human neural stem cell culture
Immortalised ReNeuron VM cells (ReN) [40] were cul-
tured on laminin-coated vessels in ReN NSC mainten-
ance medium containing B27 neural cell supplement
mix, bFGF (10 ng/ml) and EGF (20 ng/ml; Sigma Al-
drich, UK). Cells were passaged every 3–4 days using
trypsin (0.25%) and soybean trypsin inhibitor (Sigma Al-
drich) solutions. Briefly, cells were rinsed with phosphate
buffered saline (PBS) and then incubated in trypsin
(0.25%) solution for 5–15 min until the cells detached.
Twice the volume of soybean trypsin inhibitor (Sigma
Aldrich) was added and the cells were centrifuged at
500 × g for 5 min. The cell pellet was re-suspended in
fresh medium and plated in freshly laminin-coated flasks
at a density of ~ 10,000 cells/cm2. All experiments pre-
sented in this study were carried out on cells between
passages 5 and 8.
Human iPS-derived cardiomyocyte cell culture
Cardiomyocytes (CMC) [41] were thawed, transferred to
RPMI-B27 medium and centrifuged at 300 × g for 3 min.
Cells were re-suspended in RPMI-B27 containing 10 μM
ROCK inhibitor (Tocris Biotechne) and plated, with a first
medium change carried out after 48 h with RPMI-B27
only. Subsequent medium changes were carried out there-
after at intervals of 2–3 days without ROCK inhibitor.
Human cancer cell lines
HeLa (cervical cancer cell line) [42], HOS (human
osteosarcoma cell line) [43], SHSY5Y (human
neuroblastoma-derived cell line) [44] and Caco-2 (hu-
man epithelial colorectal adenocarcinoma cells) [45]
were cultured and expanded in standard culture
medium consisting of DMEM supplemented with 10% (v/
v) FBS, 1% (v/v) non-essential amino acids, 1 mM L-gluta-
mine, 1 mM pyruvate and 1% penicillin/streptomycin.
Cells were passaged using trypsin/EDTA.
Mouse embryonic stem cell culture
Mouse embryonic stem cells (ESC) were cultured in
DMEM supplemented with 1.7 mM L-glutamine, 0.1 mM
β-mercaptoethanol, 5 ng/ml mouse leukaemia inhibitory
factor (LIF), 10% (v/v) FBS, 1% (v/v) non-essential amino
acids, 1 mM pyruvate and 1% penicillin/streptomycin
(stock 10,000 U/ml) without a feeder layer. Cells were dis-
sociated by 0.05% trypsin/EDTA.
Cell labelling with magnetic particles
Cells were seeded at 40% confluency and grown to 80%
confluency before labelling. Fluorescently tagged mag-
netic particles of 500 nm and 1000 nm (ScreenMAG-Si-
lanol, Chemicell, Germany) were used for cell labelling.
Labelling of cell monolayers was performed as described
previously [38, 46]. Briefly, adherent cell populations
were incubated with MPs (10 μg Fe/ml standard dose or
25 μg Fe/ml for fully confluent cultures) in medium for
24 h. The next day, cells were thoroughly washed with
PBS in order to remove excess particles attached to the
cell surface or flask. For suspension cell labelling, MSC,
CMC and ReN were evenly suspended in 7 ml growth
medium without serum and MPs were added at 70 μg
Fe of particles per 1 × 106 cells. Cells were agitated at 60
RPM for 3 h and labelled suspensions were then centri-
fuged to remove excess particles before plating out or
direct flow cytometry after fixation with 4% ice-cold
paraformaldehyde (PFA) (VWR, UK).
Particle labelling assessment
To measure particle uptake by flow cytometry, cells were
harvested, centrifuged at 200 × g for 5 min and
re-suspended in PBS prior to analysis. Fixed samples
from suspension labelling were analysed in PBS immedi-
ately following PFA fixation. Labelled and unlabelled
populations were compared to evaluate the percentage
uptake based on fluorescent intensity. Analysis was per-
formed on a Beckman Coulter FC500 8HT Flow Cyt-
ometer (Beckman Coulter, USA) with WEASEL (WEHI,
Australia), using unlabelled cells as controls to evaluate
increased fluorescence.
Particle uptake was further evaluated visually using
fluorescence and super-resolution microscopy. Adherent
cells from monolayer cultures or plated out after suspen-
sion culture were fixed with 4% PFA and stained using
FITC-labelled Phalloidin (Life Technologies, USA) ac-
cording to the manufacturer’s instructions [38, 47], fol-
lowing permeabilisation with 0.1% Triton X-100 for
5 min. Slides were incubated in a dark covered container
at room temperature for 15 min, and then washed twice
with PBS and counterstained with Hoechst 33342
(Sigma Aldrich, UK). Cells were then imaged using the
Operetta High Content Analysis System (Perkin Elmer,
USA). For super-resolution microscopy, CMC were
seeded in Matrigel-coated glass-bottom culture dishes
(MatTek Corporation, USA) and left to attach and beat
Harrison et al. Stem Cell Research & Therapy  (2018) 9:248 Page 3 of 13
for 3 days. Cells were then labelled with 10 μg Fe/ml for
24 h, washed three times with PBS and fixed with PFA.
MSC osteogenic differentiation
MSC were seeded at 5 × 103 cells/cm2 and the medium
was then changed every 3 days for 14 days with either
control medium or osteogenic induction medium con-
taining DMEM supplemented with 100 nM dexametha-
sone, 0.05 mM L-ascorbic acid-2-phosphate and 10 mM
β-glycerophosphate. Mineralised nodules were identified
using Von Kossa staining [48]. Cells were fixed at room
temperature for 15 min in 4% PFA, washed three times
with dH2O and incubated with 1% silver nitrate in dH2O
(Sigma Aldrich) under a UV lamp for 15 min. Samples
were washed three times with dH2O, incubated for
5 min with 2.5% sodium thiosulfate solution (Sigma Al-
drich), washed again with dH2O and imaged using an
eclipse TS100 inverted microscope (Nikon, Japan).
ReN differentiation
Cells were seeded at 10,000 cells/well onto laminin-
coated 96-well plates (BD Biosciences) and expanded for 2
days in growth medium before initiating differentiation
using ReN culture medium without growth factors [40].
After 7 days of differentiation, cells were fixed in 4% para-
formaldehyde (PFA) for immunocytochemistry analysis.
Cell viability assessment
Viability was evaluated using the resazurin metabolic
assay, using a working solution consisting of 10% (v/v)
Presto Blue stock solution prepared according to the
manufacturer’s instructions. After 45-min incubation,
the fluorescent signal of 100 μl samples was measured at
535 nm excitation and 615 nm emission in triplicate,
using an Infinite 200 PRO plate reader and i-control
software (Tecan, Switzerland). The positive control con-
sisted of unlabelled cells which remained in monolayers
for the duration of the labelling time period, and the
negative control consisted of cells exposed to 70%
methanol in H2O fixative for 10 min followed by 3× PBS
washing.
HypoThermosol refrigerated storage of cells
MSC, CMC and ReN at full confluency were removed
from the incubator and the media exchanged with 4 °C
HypoThermosol FRS preservation solution (BioLife So-
lutions, USA). Plates were then sealed with Parafilm
(Bemis NA, USA) and stored at 4 °C for 24 h. Cells were
then removed from refrigerated storage, and the
HypoThermosol solution was replaced with warmed
media. A recovery period of 48 h was then allowed prior
to assessment or fixation with 4% PFA. Assessment of
cells before and after HypoThermosol incubation was
performed using bright-field microscopy. Images and
videos were acquired using an eclipse TS100 inverted
microscope (Nikon, Japan).
Statistical analysis
Statistical analysis was in the form of ANOVA per-
formed using GraphPad PRISM (GraphPad Software,
USA). Significance was shown as *P ≤ 0.05, **P ≤ 0.01,
***P ≤ 0.001 and ****P ≤ 0.0001.
Results
Efficient cell labelling applicable to multiple cell types
Therapeutically relevant cell types were cultured with
fluorescently labelled MPs (10 μg/ml) in order to test
the broad efficiency of the labelling strategy for regen-
erative medicine applications (Fig. 1). After 24 h of incu-
bation, flow cytometry measurement showed labelling
efficiencies ranging from above 23% (Caco-2 and mouse
embryonic stem cells) to > 90% (HeLa, HOS, MSC and
SHSY5Y) (Fig. 1a–f ). Fluorescence imaging of three clin-
ically relevant human cell types—cardiomyocytes derived
from pluripotent embryonic stem cells (CMC), bone
marrow-derived mesenchymal stromal cells (MSC) and
neuroprogenitor cells (ReN)—incubated with fluorescent
MPs using the same approach confirmed the intracellu-
lar labelling after 24 h (Fig. 1g–i).
In order to assess the tolerance of these different cell
types to the labelling procedure, metabolic activity was
assessed at 24 h post labelling (Fig. 2), using 500 nm and
1000 nm MPs. No significant difference in relative viability
was observed in MSC, ReN or CMC upon incubation with
500 nm or 1000 nm MPs after 24 h (Fig. 2a–c). At the
standard 10 μg/μl concentration, cell viability was above
80%, indicating that magnetic labelling did not affect the
cell cultures. Further viability, senescence and cell cycle
profile assessments confirmed the maintenance of cellular
integrity upon labelling (Additional file 1: Figure S1). Simi-
larly, the unaffected morphology and viability of beating
CMC were confirmed through observation of beating
colonies (see methods in Additional file 2: Supple-
mentary information, and videos of beating CMC col-
onies in Additional file 3: Figure S2 and Additional
file 4: Figure S3).
Cell labelling approach for suspension cultures
In order to assess the possibility of integrating MP label-
ling strategies within existing cell manufacturing plat-
forms, labelling of cells was performed in suspension
cultures. These corresponded to the cell pooling stages,
where cells may be held in suspension between unit op-
erations of a manufacturing process [49, 50]. This was
evaluated for a range of cell types to show utility across
a range of therapeutically relevant cells.
Suspensions of ReN, MSC and CMC were incubated
with fluorescently tagged microparticles using two
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different sizes (500 nm and 1000 nm) (10 μg/ml) (Fig. 3).
Successful labelling was confirmed with fluorescent
microscopy for MSC (Fig. 3a), CMC (Fig. 3e) and
ReN (Fig. 3f ). The highest labelling levels were de-
tected in MSC, as compared to CMC and ReN, al-
though for the latter two the MP labelling was
suboptimal for the imaging filters used in the micro-
scope due to the maximum emission spectra not
overlapping with the filters present. The labelling effi-
ciency of MSC in suspension cultures was further ex-
amined by flow cytometry (Fig. 3b), which showed
over 98% labelling of both MP types. Membrane in-
tegrity assays demonstrated no significant alterations
in MSC populations after suspension labelling (Fig. 3c).
Metabolic activity assayed 24 h after cell labelling in-
dicated that MSC, CMC and ReN retained their rela-
tive viability following this suspension labelling
procedure (Fig. 3d, g, h).
Cold chain transport of therapeutically relevant labelled
cells
The final component of the manufacturing value chain is
transportation and distribution to the end user. This often
overlooked step occurs outside the manufacturing facility
and is a significant risk factor for introducing unknown
changes to the final cell therapy product. The final stage
transport of therapeutically relevant labelled cells was ex-
amined using HypoThermosol FRS as a transport medium
in refrigerated environments. MSC, CMC and ReN were
labelled with MP and stored in HypoThermosol preserva-
tion medium for 24 h at 4 °C to evaluate subsequent via-
bility, functionality and label retention. Following a 24-h
recovery period at 37 °C, cells were examined for meta-
bolic activity as a measure of their relative viability (Fig. 4).
No statistically significant decrease was detected in rela-
tion to the hypothermic incubation step, suggesting cells
returned to basic metabolic activity post storage.
G H I
A B
C D
E F
Fig. 1 Microparticle-based labelling of adherent cultures incubated for 24 h in medium containing 1000 nm MPs (10 μg/μl). a–f Flow
cytometry measurement of labelled (pink) and unlabelled (blue) cell populations analysed 24 h post incubation: a HeLa (cervical cancer
stem cell line), b pMSC (primary mesenchymal stem cells), c HOS (human osteosarcoma stem cell line), d mESC (mouse embryonic
stem cells), e SHSY5Y (human neuroblastoma derived stem cell line), f Caco-2 (human epithelial colorectal adenocarcinoma cells).
Representative data shown, n = 3. g–i Fluorescence microscopy observation of neuroprogenitors (ReN, g), mesenchymal stem cells
(MSC, h), and iPS-derived cardiomyocytes (CMC, i) incubated overnight with MPs (gold), stained with Phalloidin (green) and Hoechst
33342 (blue)
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It is crucial that cells remain not only viable but also
functional. Previous work has examined tri-lineage dif-
ferentiation of MSCs with and without iron MP label-
ling, demonstrating no impairment on the cells’ ability
to differentiate [38, 46]. Thus, a simple indicator of func-
tionality was examined for each cell type following the
low-temperature storage (Fig. 5). MSC function was in-
dicated using an osteogenic differentiation assay applied
post 24-h storage. Von Kossa staining at day 14
highlighted mineralisation and the retention of their dif-
ferentiation ability following labelling and storage of cells
(Fig. 5a). Differentiation of the ReN carried out for 7 days
post 24-h hypothermal storage indicated that both un-
labelled and MP-labelled cells retained their ability to
differentiate towards neuronal and glial lineages
(Fig. 5b).
The morphology and functional ability of CMC to
spontaneously beat was observed through bright-field
imaging after 24 h (Additional file 5: Figure S4).
This was further characterised through quantitation
of alpha actinin immunodetection, which demon-
strated expression in CMC following HypoThermosol
incubation, albeit at a reduced level (Additional file 6:
Figure S5).
Discussion
Micron-sized iron oxide particles have demonstrated
excellent utility for tracking by MRI, and early re-
search suggests they have additional utility as thera-
nostic agents [7, 51, 52]. Future cell therapies will
require the adoption of scalable manufacturing pro-
cesses enabling large-scale, reproducible manufacture
[5, 53] that can be integrated into the manufacturing
value chain rather than added post production, such
as cell labelling [54].
Here, an approach to label a range of cell types effi-
ciently with MPs was investigated. Labelling for 24 h
was shown to be effective, and noted to be more efficient
for larger cell types such as HeLa cells or MSC when
compared to relatively smaller cells such as mouse em-
bryonic stem cells or Caco-2 cells. When examining
three therapeutically relevant human cell types, this was
further confirmed as the smaller neuroprogenitor cells
were observed to take up fewer particles than the larger
CMC or MSC. Despite this, efficient MP labelling was
demonstrated in monolayers for the MSC, CMC and
Fig. 2 Metabolic activity measurements of MSC (a), CMC (b) and
ReN (c) cultures at 24 h post labelling using 500 nm and 1000 nm
MPs at a range of concentrations (a, b) including the standard
10 μg/ml dose (c). Error bars presented as SEM, n = 8 (a, b) and n = 3
(c). *P ≤ 0.05, **P ≤ 0.01, ****P ≤ 0.0001. MP magnetic particle
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ReN cell types. Whilst the relationship between particle
size and particle uptake is known [55], previous litera-
ture has reported that biological indicators such as cell
density and proliferative state can affect uptake [56];
however, the role of cell size is less clear and may in-
volve indirect links between biological processes and the
MP physicochemical properties [57]. The reduced MP
uptake in ReN may be related to their reduced ability to
store particles in a reduced cytoplasmic volume [58], as
internalised MPs have been shown to accumulate into
perinuclear intracellular vesicles [38].
The maintenance of cell integrity upon labelling was
confirmed by metabolic activity assays, found in agree-
ment with a lack of senescence or cell cycle perturbation
responses. These data are also in line with a lack of de-
tectable DNA damage upon labelling [38]. Whilst iron
A
B
E
F
G H
C D
Fig. 3 Development of suspension cell labelling approach for human cells. a, b MP-labelled MSC examined by fluorescence microscopy 24 h
post labelling (a), after staining with Phalloidin (green) and Hoechst 33342 (blue), and by flow cytometry (b). c, d MSC viability examined by
membrane integrity assay (c) and metabolic activity measurement (d) 24 h post labelling. Viable control consisted of unlabelled monolayer cells,
Toxicity control consisted of cells exposed to 70% methanol for 10 min. e, f Fluorescence microscopy evaluation of CMC (e) and ReN (f) following
suspension labelling with 500 nm (middle panel) or 1000 nm (right panel) MPs (gold) compared to unlabelled cells (left panel), with Phalloidin
(green) and Hoechst 33342 (blue) counterstain. g, h Metabolic activity for CMC (g) and ReN (h) 24 h post suspension labelling. Error bars presented as
SEM, n = 3. **P≤ 0.01. MP magnetic particle
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particles have been suggested to cause oxidative damage
leading to senescence in MSC populations [59], the re-
sults presented here are in line with previous reports
suggesting there is no significant adverse effect on cells
[38, 60, 61]. Both MSC and CMC demonstrated toler-
ance of MPs up to 100× standard dose (1000 μg/ml)
which then led to a 50% reduction in relative viability. In
CMC, the 500 nm particles appeared to be more toxic
than the 1000 nm particles. This could be linked to the
increased surface area for smaller particles, previously
hypothesised to lead to membrane wrapping effects [62,
63] and binding of a larger number of cell proteins [64].
ReN tolerated standard doses of MPs (10 μg/ml) with no
reduction in viability; however, higher doses had a not-
able deleterious effect on cell attachment, preventing ef-
fective assessment. Overall, these findings are in line
with the wider literature, reporting enhanced tolerance
to MP labelling for MSC [38] and CMC [65]. Con-
versely, it has been suggested that neural stem cells are
more susceptible to the iron contained in particles
through an oxidative stress mechanism [65, 66]. Further
assessments such as evaluation of senescence, apoptotic
and autophagy responses could provide complementary
parameters to assess and compare the finer cellular ef-
fects of high MP doses on different cell types.
CMC were further shown to maintain their functional
capacity to beating following MP labelling, and cells
were seen to change their morphology at doses exceed-
ing 100 μg/ml but retained the ability to beat at even the
highest dose (1000 μg/ml). Previous research on mag-
netic tissue engineering of cardiac sheets has investi-
gated the effect that 10 nm magnetite particles may have
on electrical connections between cells which may affect
beating. This demonstrated no adverse effect [67], con-
firming our observations. Previous studies have sug-
gested MSC function remains following MP labelling,
with cells able to undergo multi-lineage differentiation
into osteogenic, adipogenic and chondrogenic cell types
[38]. This varies between studies, however, with some re-
search groups demonstrating reduced markers of func-
tion including colony forming ability and differentiation
potential [68]. This is likely due to the highly variable
nature of MPs used throughout the field as well as a
strong dose-responsive relationship between MPs and
function [65]. Neural cells seem to have a reduced toler-
ance of labelling procedures, yet limited data suggest
they do retain some function post labelling, with a study
investigating MRI of transplanted labelled cells demon-
strating substantial migration over time in vivo [69].
Efforts have been made to find clinically suitable label-
ling methods for iron oxide-based particles to ensure
they effectively label the desired cell populations. For
certain particles, which do not interact with cells, the
use of a transfection agent to enhance labelling has
proved successful [70]. Here we used an approach enab-
ling the autonomous magnetic labelling of cells without
the addition of other agents to the manufacturing
process [38], and demonstrated its effectiveness in
monolayers as well as suspension cultures for three hu-
man cell types. Suspension labelling demonstrated not
only effectiveness but also retention of relative cell via-
bility, with no statistically significant reduction when
compared to unlabelled populations. This demonstration
is of particular significance given the expected commer-
cial significance of suspension culture methods such as
stirred tank [50] or rocking WAVE® [71] bioreactors.
These technologies represent an opportunity to signifi-
cantly drive down the production cost of goods [72] and
thus enhance market adoption of cell therapy [50], so
the applicability of this labelling process represents an
attractive route for integrating MPs with cell therapies.
When compared to monolayer MSC labelling, suspen-
sion cultures demonstrated a reduction in viability in all
suspension populations, in the presence or absence of
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Fig. 4 Metabolic activity measurements of MP-labelled MSC (a), CMC (b) and ReN (c) after 24 h in HypoThermosol conditions. Error bars
presented as SEM, n = 6
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MPs, suggesting the cell pooling phase may require opti-
misation rather than the labelling process itself. Previous
approaches have worked to bypass the requirement of
adherent cell cultures for labelling success, instead opt-
ing for functionalised particle surfaces which drive tar-
geted uptake through receptor mediated methods [73].
Both the 500 nm and the 1000 nm particles used
here were shown to rapidly label adherent cultures
and suspension culture. This suspension labelling
methodology reduces the necessity for specific particle
surface functionalisation in order to convey cell up-
take traits. Rather, the particles are spontaneously
taken up, which would allow functionalisation steps
to be avoided.
In order to replicate the final step of a potential clinical
therapy, the cell transport phase to the point of care, a
low-temperature storage process was tested on MP-labelled
cells using the HypoThermosol FRS product. This has pre-
viously been shown to maintain viability of a range of un-
labelled cells such as pluripotent derived cardiac [74],
mesenchymal [75] and neural [76] cell types. Here hypo-
thermal exposure was tested on MP-labelled cells, and indi-
cators of viability and function were examined.
MP-labelled neuroprogenitors were demonstrated to
retain the ability to readily differentiate following simu-
lated cold chain transport, as seen for unlabelled cells.
This is in line with previous findings which demon-
strated a retention of differentiation capacity following
Fig. 5 Assessment of labelled MSC and ReN after HypoThermosol storage for 24 h. a Differentiation of ReN analysed by immunodetection for
MAP2, GFAP and β3-tubulin expression following a 7-day differentiation protocol. Additional examination of CMC forming beating cardiomyocyte
clusters and analysis of alpha actinin expression in MP-labelled cell populations exposed to HypoThermosol storage shown in Additional file 5:
Figure S4. b Osteogenic differentiation of MP-labelled MSCs for 14 days, post incubation in HypoThermosol analysed using Von Kossa staining to
highlight mineral deposits formed after 14 days under induction treatment. Scale bar = 125 μm
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labelling [77]. Additionally, whilst both studies demon-
strate retention of differentiation capacity, there are
likely underlying long-term biological consequences.
This is reflected in the observations during this research
and previous literature [77] showing changes to cell
morphology. This is potentially driven by the production
of reactive oxygen species by the iron particles within
the cells which are able to alter the internal regulatory
mechanisms of neural stem cells [78].
Particle toxicity has previously been reported in neur-
onal and glial cell types [79]. In this study, MSC demon-
strated retention of their ability to expand and form
osteogenic cultures upon treatment. This is in line with
previous published reports demonstrating retention of via-
bility, colony forming ability and differentiation capacity
of MSC populations following labelling with micron-sized
iron oxide particles [80]. Additionally, the outcome of the
osteogenic assay is in agreement with our previous obser-
vation that human MSC retain the ability to differentiate
to all three lineages post labelling [38].
MP-labelled CMC were shown to remain functionally
active following this hypothermal step, with cells resum-
ing their beating activity when returned to normal cul-
ture conditions. When this was further examined with
alpha actinin detection, it was noted that population
purity had decreased, suggesting that storage may be af-
fecting the mature CMC population to some degree.
This contrasts with existing findings which reported
CMC could tolerate similar hypothermal storage for up
to 7 days [74], and suggests this slight decrease may be
due to the presence of iron particles within the cells.
Demonstrating the applicability of labelled cells for
hypothermic storage is important in qualifying their
use for this transport methodology. Hypothermic stor-
age represents an attractive solution for cellular deliv-
ery as it removes any cryopreserved resuscitation
step, thus simplifying the final formulation step at the
clinical site [81].
Conclusion
Future prospects for precision medicine and regenerative
medicine through the use of MPs are promising, and re-
quire careful process validation to ensure clinical need is
addressed in the early stage of manufacturing design. This
study suggests MP labelling could be incorporated into a
cell manufacturing process for a range of therapeutically
relevant cell types. Furthermore, MP-labelled cell popula-
tions were shown to withstand low-temperature storage
without significantly impacting indicators of cell function,
suggesting the process would be compatible with cold
chain transport. These results suggest that MP-based ther-
anostics can be effectively integrated into cell manufactur-
ing processes to support their use in future potential cell
therapies.
Additional files
Additional file 1: Figure S1. Maintenance of cell integrity after cell
labelling with 1000 nm SiMAG for MSC. (A) Live/dead cell assay (live,
green; dead, red) showing live cell fractions remaining above the toxicity
threshold (dashed line). Scale bar: 100 μm. (B) Senescence assay (blue
signal) showing no significant change upon labelling. Scale bar: 50 μm.
(C) Cell cycle analysis showing no significant difference between unlabelled
and labelled cell populations. **p < 0.01, ***p < 0.001 (TIF 445 kb)
Additional file 2: Supplementary materials and methods (DOCX 14 kb)
Additional file 3: Figure S2. Beating cardiomyocyte cell cluster showing
particles distributed across its mass. Demonstration of viable beating cells
with fluorescent particles allowing imaging and tracking of particles in real
time. Cells stained with Calcein AM (green) and labelled with SiMAG (red)
(WMV 6783 kb)
Additional file 4: Figure S3. Video of beating CMC colonies. Morphology
and ability of cardiomyocytes to beat following labelling demonstrated that
cells retain the ability to beat even at the highest doses (WMV 4259 kb)
Additional file 5: Figure S4. Cardiomyocytes labelled with SiMAG
resuming beating following refrigerated storage. Following incubation of
cardiomyocytes with HypoThermosol in refrigerated conditions, cells
were assessed to determine whether they resumed beating. They were
found to beat within 12 h of being removed from refrigerated storage
even when labelled with SiMAG (WMV 7173 kb)
Additional file 6: Figure S5. Assessment of labelled CMC after
HypoThermosol storage for 24 h. Image analysis performed examining
alpha actinin expression in MP-labelled cell populations exposed to
HypoThermosol storage. Error bars presented as SEM, n = 3 (TIF 25 kb)
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